What is the best next step in treatment for a patient who now has mildly reduced left ventricular systolic function with an ejection fraction of 45‑50% (previously 69%), normal right ventricular function, no patent foramen ovale, no significant valvular disease, a normal ascending aorta, and no pericardial effusion?

Initiate Guideline-Directed Medical Therapy for New-Onset Heart Failure with Mildly Reduced Ejection Fraction

This patient has transitioned from normal LVEF (69%) to HFmrEF (45-50%) and requires immediate initiation of foundational guideline-directed medical therapy (GDMT) consisting of: (1) an SGLT2 inhibitor, (2) an ACE inhibitor or ARB (or preferably ARNI if symptomatic), (3) a beta blocker, and (4) a mineralocorticoid receptor antagonist if symptoms persist after initial therapy. 1, 2

Classification and Staging

This patient now has HFmrEF (LVEF 41-49%) based on the 2022 ACC/AHA/HFSA guidelines 2. The decline from 69% to 45-50% represents new-onset left ventricular systolic dysfunction. According to the staging system, this patient is at minimum Stage B (pre-heart failure with structural heart disease and reduced systolic function) and potentially Stage C if any symptoms are present 1.

Immediate Treatment Algorithm

First-Line Foundational Therapy (Initiate Simultaneously)

1. SGLT2 Inhibitor - Start immediately regardless of diabetes status

   • Dapagliflozin 10 mg daily or empagliflozin 10 mg daily
   • This class reduces cardiovascular mortality and heart failure hospitalizations across the entire LVEF spectrum 1, 3, 4
   • No titration needed; use target dose from initiation

2. ACE Inhibitor or ARB (or ARNI if symptomatic)

   • Start with ACE inhibitor (e.g., lisinopril 2.5-5 mg daily, enalapril 2.5 mg twice daily)
   • Titrate to target doses over 6-12 weeks 1, 5
   • If patient has symptoms, consider angiotensin receptor-neprilysin inhibitor (ARNI) as superior alternative 4, 5

3. Evidence-Based Beta Blocker

   • Carvedilol, metoprolol succinate, or bisoprolol
   • Start low (e.g., carvedilol 3.125 mg twice daily, metoprolol succinate 12.5-25 mg daily)
   • Titrate to target doses over 6-12 weeks 1, 5

4. Mineralocorticoid Receptor Antagonist - Add if symptoms persist

   • Spironolactone 12.5-25 mg daily or eplerenone 25 mg daily
   • Monitor potassium and renal function closely 1, 5

Critical Timing Consideration

All foundational therapies should be initiated within 6-12 weeks of diagnosis with aggressive uptitration to target doses 5. Do not delay initiation waiting for "stability" - early treatment prevents further deterioration.

Essential Diagnostic Workup Before Treatment

Before initiating therapy, determine:

• Etiology of cardiomyopathy: Ischemic vs. non-ischemic (coronary angiography or stress testing if not recently done)
• Symptom assessment: NYHA functional class to determine Stage C vs. Stage B
• Baseline labs: BNP/NT-proBNP, potassium, creatinine, complete blood count
• Iron studies: Ferritin and transferrin saturation (iron deficiency common and treatable) 5

Evidence Strength and Nuances

The 2022 ACC/AHA/HFSA guidelines 1, 2 provide Class 1 recommendations for SGLT2 inhibitors in patients with type 2 diabetes at cardiovascular risk to prevent HF hospitalizations. For patients with established HFmrEF, SGLT2 inhibitors have shown benefit across the LVEF spectrum 3, 6, 4.

Important distinction: While this patient has HFmrEF (LVEF 41-49%), the treatment approach mirrors HFrEF management. The guidelines explicitly state that patients with LVEF ≤40% should receive ACE inhibitors/ARBs, beta blockers, and mineralocorticoid receptor antagonists 1. Given this patient's LVEF is borderline (45-50%), aggressive GDMT is warranted to prevent further decline.

Common Pitfalls to Avoid

1. Sequential rather than simultaneous initiation: Start all foundational therapies together, not one at a time. Waiting months between medications delays benefit and allows disease progression.

2. Undertitration: Aim for target doses proven in clinical trials, not just "some dose." Most mortality benefit comes from target dosing 5.

3. Premature discontinuation for mild adverse effects:

   • Mild hypotension (SBP 90-100 mmHg) without symptoms is acceptable
   • Creatinine increases up to 30% from baseline are tolerable if stable
   • Potassium up to 5.5 mEq/L can be managed with dietary modification and diuretic adjustment 5

4. Ignoring iron deficiency: Check iron studies and replace if deficient (ferritin <100 ng/mL or ferritin 100-300 ng/mL with transferrin saturation <20%) to improve functional status 5.

5. Delaying treatment in "asymptomatic" patients: Stage B patients (structural disease without symptoms) still require GDMT to prevent progression to symptomatic heart failure 1.

Monitoring Strategy

• Week 1-2: Assess for symptomatic hypotension, check potassium and creatinine
• Weeks 2-6: Uptitrate beta blocker and ACE inhibitor/ARB to target doses
• Week 6-12: Add mineralocorticoid receptor antagonist if symptomatic; continue uptitration
• 3 months: Repeat echocardiogram to assess response; check BNP/NT-proBNP
• 6 months: Reassess LVEF - if improved to >40%, patient has HFimpEF and should continue all GDMT as EF can decline again with medication withdrawal 2

Additional Considerations

If the patient has diabetes and chronic kidney disease, consider adding finerenone (a non-steroidal mineralocorticoid receptor antagonist) to reduce heart failure hospitalizations 3.

If iron deficiency is identified, intravenous iron replacement improves functional status and quality of life in HFmrEF 3, 5.

The absence of PFO, significant valvular disease, and pericardial effusion simplifies management - focus is purely on medical optimization for cardiomyopathy.